Teladoc Health Inc (NYSE:TDOC) SVP Andrew Turitz Sells 2,778 Shares

Teladoc Health Inc (NYSE:TDOC) SVP Andrew Turitz sold 2,778 shares of the firm’s stock in a transaction dated Friday, June 19th. The stock was sold at an average price of $200.00, for a total value of $555,600.00. Following the sale, the senior vice president now owns 6,793 shares of the company’s stock, valued at $1,358,600. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Andrew Turitz also recently made the following trade(s):

  • On Thursday, April 16th, Andrew Turitz sold 14,122 shares of Teladoc Health stock. The stock was sold at an average price of $168.41, for a total value of $2,378,286.02.

Shares of TDOC stock opened at $201.70 on Friday. The stock’s 50 day simple moving average is $177.87 and its 200 day simple moving average is $134.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.14 and a current ratio of 6.14. Teladoc Health Inc has a twelve month low of $54.58 and a twelve month high of $208.63. The company has a market capitalization of $14.74 billion, a price-to-earnings ratio of -149.41 and a beta of 0.44.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, April 29th. The health services provider reported ($0.40) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.35) by ($0.05). The business had revenue of $180.80 million during the quarter, compared to analyst estimates of $180.64 million. Teladoc Health had a negative net margin of 16.24% and a negative return on equity of 10.60%. The business’s quarterly revenue was up 40.6% compared to the same quarter last year. During the same period last year, the business earned ($0.43) EPS. On average, analysts forecast that Teladoc Health Inc will post -1.12 EPS for the current fiscal year.

A number of equities research analysts have commented on the company. JPMorgan Chase & Co. raised their price objective on Teladoc Health from $182.00 to $194.00 and gave the stock an “overweight” rating in a research report on Thursday, April 30th. Zacks Investment Research lowered Teladoc Health from a “buy” rating to a “hold” rating and set a $171.00 price objective for the company. in a research report on Thursday, May 28th. Bank of America raised their price objective on Teladoc Health from $106.00 to $140.00 and gave the stock a “neutral” rating in a research report on Thursday, February 27th. UBS Group raised their price objective on Teladoc Health from $119.00 to $185.00 and gave the stock a “neutral” rating in a research report on Thursday, April 30th. Finally, Cowen raised their price target on Teladoc Health from $175.00 to $197.00 and gave the stock an “outperform” rating in a research note on Thursday, April 30th. Fifteen equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $161.58.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. State Street Corp grew its holdings in Teladoc Health by 0.6% in the 1st quarter. State Street Corp now owns 1,487,275 shares of the health services provider’s stock valued at $230,542,000 after buying an additional 8,764 shares during the last quarter. Cunning Capital Partners LP acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $1,085,000. Pathstone Family Office LLC acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $31,000. 1832 Asset Management L.P. acquired a new stake in Teladoc Health in the 1st quarter valued at approximately $2,750,000. Finally, The Manufacturers Life Insurance Company grew its holdings in Teladoc Health by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 45,418 shares of the health services provider’s stock valued at $7,040,000 after buying an additional 2,806 shares during the last quarter. 97.66% of the stock is currently owned by hedge funds and other institutional investors.

About Teladoc Health

Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Read More: Average Daily Trade Volume – What You Need to Know

Insider Buying and Selling by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.